Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer
January 1, 2008
Does chemotherapy improve OS over EBRT in women with intermediate/high risk endometrial cancer?
cyclophosphamide 333mg/m2
doxorubicin 40mg/m2
cisplatin 50 mg/m2
q4wks x3+ cycles
Pelvic EBRT 4500-5000cGy
OS
stage IC-IIIC endometrioid endometrial carcinoma
>50% myometrial invasion
TAH/BSO with no residual tumor
chemo vs RT:
5yr PFS: 82% vs 83% (NS)
5yr OS: 87% vs 85% (NS)
High intermediate risk group, 5yr PFS (84% vs 66%, SS) and 5yr OS (90% vs 74%, SS) improved with CAP
Defined as: (1) stage IC and >70yo or G3, (2) stage II or IIIA (positive cytology) with >50% myometrial invasion
similar rates of adverse events
Adjuvant chemotherapy improved OS in women with high intermediate risk endometrial cancer.